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Background: Epithelial ovarian cancer (EOC) is an aggressive disease with poor prognosis. The expression of
cytokine-induced apoptosis inhibitor 1 (CIAPIN1) correlates with the malignant progression of several cancers.
However, the relationship between the subcellular localization of CIAPIN1 and clinical characteristics in EOC remains
unclear.
Methods: Immunohistochemistry was performed to detect CIAPIN1 expression in 108 EOC tissues. CIAPIN1
expressions in eight fresh EOC tissues were detected by Western blotting. The relationship between CIAPIN1
subcellular expression and patients’ clinicopathological features, including prognosis, was evaluated.
Immunohistochemistry and immunofluorescence were employed to assess the CIAPIN1 subcellular localization in
the EOC cell lines A2780 and HO8910. In addition, all patients were followed up to assess the prognostic value of
CIAPIN1 in patients with EOC.
Results: CIAPIN1 is highly expressed in EOC, but is present at low levels in paired non-cancerous ovarian epithelial
tissues. The results of Western blotting were in accordance with the immunohistochemical results. Poor
differentiation of the tumors and EOC cell lines correlated with higher levels of CIAPIN1 nuclear expression. CIAPIN1
nuclear expression significantly correlated with the Federation International of Gynecology and Obstetrics (FIGO)
stage and histological differentiation (P= 0.034 and P< 0.0001, respectively). Moreover, nuclear localization of
CIAPIN1 was selected as an unfavorable prognostic factor by both univariate and multivariate analyses (P< 0.001).
However, no significant correlations were observed between cytoplasmic localization of CIAPIN1 and
clinicopathological parameters.
Conclusions: CIAPIN1 might play a crucial role in the differentiation of EOC cells. Elevated expression of nuclear
CIAPIN1 negatively correlated with the survival of EOC patients, suggesting that nuclear CIAPIN1 might serve as a
prognostic biomarker for EOC patients.
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EOC is the fourth leading cause of cancer-related deaths
among women worldwide [1,2]. Despite considerable
advances in surgical techniques and neoadjuvant chemo-
therapy, overall patient treatment outcomes have not sub-
stantially improved [3]. EOC remains a clinical challenge,
primarily because of the absence of effective methods for
early diagnosis and lack of prognostic markers. Therefore,* Correspondence: xiaoyan_973@163.com
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reproduction in any medium, provided the oradditional efforts are required to identify biomarkers for
predicting poor outcome in EOC.
CIAPIN1, a novel anti-apoptotic molecule, has been
identified to be a downstream effector of the receptor
tyrosine kinase-Ras signaling pathway in the mouse Ba/
F3 pro-B cell line [4]. CIAPIN1 has been demonstrated
to be ubiquitously distributed in normal fetal and tumor
tissues, with high expression in actively metabolic tissues
[5,6]. Therefore, CIAPIN1 is likely involved in important
physiological functions in tumors. Additionally, a previ-
ous study has shown that CIAPIN1 is localized not only
in the cytoplasm, but also in the nucleus, and the authors
suggest that subcellular localization of CIAPIN1 might. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Correlation between CIAPIN1 nuclear expression
and clinicopathological parameters (P<0.05 statistically
significant)
Parameters Total Nucleus expression
− + ++ +++ p-value
Age 0.748
<53 59 7 16 23 13
≥53 49 3 16 19 11
Pathology subtypes 0.517
Serous cyst 45 3 16 15 11
Other types 63 7 16 27 13
FIGO stage 0.034
I + II 55 6 20 23 6
III + IV 53 4 12 19 18
Histological differentiation <0.0001
Well 33 7 11 15 0
Moderately 33 2 5 21 5
Poorly 42 1 16 6 19
Lymph node status 0.523
Positive 27 4 9 10 4
Negative 81 6 23 32 20
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has been demonstrated to be a critical molecule involved
in tumor aggressiveness and may represent a prognostic
marker for patient outcome in several types of cancer,
such as hepatocellular cancer [8] and leukemia [9]. In re-
cent studies, the significance of CIAPIN1 has been iden-
tified in tumors such as esophageal cancer and colorectal
cancer; however, the correlations were detected between
the expression level of CIAPIN1 in both the nucleus and
cytoplasm, and tumor clinicopathological features. CIA-
PIN1 subcellular localization has not been examined in
tumors. Therefore, improved knowledge of the subcellu-
lar localization of CIAPIN1 in tumors will be instrumen-
tal for the design of optimal strategies to selectively
disrupt CIAPIN1 in human cancers.
The clinical significance of CIAPIN1 subcellular
localization has not yet been examined in EOC. In this
context, this study evaluated the expression of CIAPIN1
in EOC tissues and analyzed the clinical significance of
the subcellular localization of CIAPIN1. Our data revealed
that CIAPIN1 nuclear localization might provide add-
itional information regarding EOC patient outcome, and
represents a valuable biomarker for diagnosis and post-
operative predictions of EOC.
Methods
A total of 108 EOC tissues and paired non-cancerous tis-
sues from primary EOC patients were surgically obtained
between 1998 and 2006 in Xijing Hospital, the Fourth Mili-
tary Medical University, Xi’an, China. The median patient
age was 53 years (range: 32–68 years). All patients agreed
to the procedure and signed consent forms. This study was
authorized by the Hospital’s Protection of Human Subjects
Committee. No patient had received chemotherapy or radi-
ation therapy prior to surgery. All of the patients died of
EOC.
The tissue specimens were obtained from surgery,
formalin-fixed and paraffin-embedded. The paired non-
cancerous tissues were epithelial tissues from ovarian biop-
sies or ovarian surface scrapings. Each sample was cut in 4-
μm sections, and one section was stained with hematoxylin-
eosin and used for morphological diagnosis. Patients’ charac-
teristics, such as age, FIGO stage, histological differentiation,
lymph node status and pathology subtype, were obtained
from the medical records. The patient characteristics are
summarized in Table 1. The diagnosis of EOC was con-
firmed by histological analysis by three pathologists. The sur-
vival information from the postoperative follow-up of all 108
patients was received by telephone or mail. The median
follow-up time was 34 months (range: 6–86 months). An
additional eight intraoperative fresh EOC tissues and paired
non-cancerous ovarian epithelial tissues were excised, and
immediately stored in liquid nitrogen for Western blotting
analysis.Immunohistochemistry (IHC)
Immunohistochemistry (IHC) staining was performed as
previously described [10,11]. The primary mouse mono-
clonal anti-CIAPIN1 antibody (dilution 1:800) was devel-
oped in our laboratory [12]. Mouse anti-immunoglobulin
G (Pierce, Rockford, IL, USA) was used as the negative
control. An anti-APE1 mouse monoclonal antibody
(1:5,000; Novus Biological, Littleton, CO) was used as the
positive control. Each tissue specimen was de-waxed twice
with xylene and gradually hydrated. After using a pressure
cooker with 10 nM citrate buffer (PH 6.0) for 5 min, the
immunostaining procedure was performed. Endogenous
peroxidases were blocked with 3% H2O2-methanol for
10 min, and the samples were incubated with the primary
monoclonal antibody overnight at 4 °C, rinsed three times
for 5 min in phosphate-buffered saline (PBS) and incu-
bated with a horseradish peroxidase-conjugated anti-IgG
antibody (1:4,000; Santa Cruz) for 1 h. Finally, the sections
were developed with diaminobenzidine solution for 2 min,
washed briefly in running water, counterstained with
hematoxylin, dehydrated through a graded series of alco-
hol to xylene and coverslipped. Three pathologists who
did not know the clinical features or survival status of the
patients then viewed the stained tissue slides separately.
To clarify the association between CIAPIN1 subcellu-
lar localization and clinicopathological characteristics,
the nuclear and cytoplasmic expression of CIAPIN1 was
examined and evaluated separately. An immunoreactiv-
ity score (IRS) system was applied using the following
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scored by estimating the proportion of tumor cells with
positive nuclear staining (0, none; 1, ≤10%; 2, 10 to ≤
25%; 3, 26 to ≤ 50%; and 4, >50%). The proportion score
was based on the proportion of tumor cells with positive
cytoplasmic staining (0, none; 1, ≤10%; 2, 10 to ≤ 25%; 3,
26 to ≤ 50%; and 4, >50%). (2) The intensity score was
assigned for the average intensity of positive tumor cells
(colorless scored 0, pallid scored 1, yellow scored 2, and
brown scored 3). The nuclear or cytoplasmic score for
CIAPIN1 was the product of the proportion and inten-
sity scores, ranging from 0 to 12. The immunoreactivity
scoring was ranked as absent (−, score 0), weak (+, score
1–4), moderate (++, score 5–8) or strong (+++, score 9–
12) according to the proportion and staining intensity.
Images were obtained under a light microscope (Olym-
pus BX51, Tokyo, Japan) equipped with a DP70 digital
camera.
Western blotting analysis
Eight intraoperative fresh EOC specimens and paired
non-cancerous ovarian epithelial specimens were soni-
cated with an ultrasonic tissue disrupter in lysis buffer
for 30 min. The tissue debris was pelleted by centrifuga-
tion, and supernatants were collected. The total protein
(30 ug was separated by 12% SDS-polyacrylamide gel
electrophoresis for 45 min and electroblotted onto a
nitrocellulose membrane for 30 min. Non-specific bind-
ing was blocked with 5% non-fat milk in TBS for 1 h at
room temperature. Then, the membrane was hybridized
using the primary antibodies Mab CIAPIN1 (1:2,000) or
β-actin (1:4,000, Sigma) overnight at 4 °C. After three
washes with TBS-T, the NC membrane was incubated at
room temperature for 1.5 h with HRP-conjugated goat
anti-mouse antibodies. The membrane was rinsed three
times with TBS-T for 25 min, and specific protein bands
were visualized using ECL (Santa Cruz Biotechnology,
Inc.) and a Bio-Rad (Thermo, USA) system.
Immunofluorescence (IF)
The A2780 cell line was originally derived from a female
ovarian adenocarcinoma, and the HO8910 cell line was
originally derived from a female ovarian serous carcinoma.
These two cell lines were preserved in our laboratory.
Cells were seeded on glass cover slips in six-well plates
and cultured in high-glucose Dulbecco’s modified Eagle's
medium (HyClone, Thermo, UT) supplemented with 10%
(V/V) fetal calf serum (FCS, Sigma), 100 IU/ml penicillin
and 100 mg/ml streptomycin at 37 °C in a humidified
chamber with 5% CO2. Afterward, the cells were fixed by
incubation in 4% paraformaldehyde for 5 min and per-
meabilized in PBS containing 0.1% Triton X-100 for
10 min. Non-specific binding was blocked with 10% BSA
for 30 min. CIAPIN1 was stained using a 1:800 dilution ofthe antibody in 1% BSA overnight at 4 °C. A mouse FITC-
conjugated phalloidin secondary antibody (Invitrogen)
was then used at a 1:1,000 dilution and incubated for 2 h
in a humidified chamber with minimal exposure to light.
All washes were performed in 1× PBS. An anti-fade solu-
tion containing DAPI (Vector Laboratories, CA) was used
in mounting the slides. Images were taken with a fluores-
cence microscope (Olympus BX51, Tokyo, Japan), and
Adobe Photoshop was used to merge the images.
Statistical analysis
Nominal variables were compared using the χ2 test, and
ordinal categorical variables were evaluated by a non-
parametric Spearman’s rank test. The survival probabil-
ities of patients were described by Kaplan-Meier curves
and compared using the log-rank test. The Cox propor-
tional hazards model with likelihood ratio statistics was
employed to further evaluate the risk factors for survival.
Two-tailed P< 0.05 was considered to be statistically
significant. The SPSS18.0 software package (SPSS, Inc.,
Chicago, IL) was used for the statistical analyses.
Results
Elevated expression of CIAPIN1 in EOC
CIAPIN1 expression was investigated by IHC in 108
EOC tissues and paired non-cancerous tissues. Positive
CIAPIN1 staining was ubiquitously observed in both the
cytoplasm and the nucleus of EOC cells (Figure 1). In
the paired non-cancerous tissues, negative expression of
CIAPIN1 was detected in 45.3% (49/108) of the speci-
mens. In contrast, negative nuclear expression of CIA-
PIN1 was observed in 9.3% (10/108) of the specimens,
and negative cytoplasmic expression of CIAPIN1 was
observed in 37.0% (40/108) of the cases. CIAPIN1 nu-
clear expression was significantly elevated in EOC com-
pared with paired non-cancerous samples (P< 0.001),
but CIAPIN1 cytoplasmic expression in EOC was not
significantly different from that in paired non-cancerous
tissues (P> 0.05). In the ovarian cancer tissues, positive
nuclear immunoreactivity was observed in 98 (90.7%)
specimens, with 32 (30%) displaying weak (+) positive
expression, 42 (39%) moderate (++) positive expression
and 24 (22%) strong (+++) positive expression. In con-
trast, positive nuclear immunoreactivity was observed in
68 (37%) samples, with 30 (28%) displaying weak (+)
positive expression, 22 (20%) moderate (++) positive ex-
pression and 16 (15%) strong (+++) positive expression.
Quantitative analysis of CIAPIN1 expression in clinical
specimens
To confirm the immunohistochemical results, we further
performed Western blotting on ovarian cancer specimens
and paired non-cancerous ovarian epithelial specimens. As
expected, the results supported the immunohistochemical
Figure 1 Expression of CIAPIN1 in EOC tissues and paired non-cancerous tissues by immunohistochemistry. (a) Negative staining (−) of
CIAPIN1 in paired non-cancerous tissues. (b) Positive staining (+) of CIAPIN1 in the nucleus in well-differentiated tumor tissue. (c) Moderate
nuclear positive staining (++) of CIAPIN1 in moderately differentiated EOC tissues. (d) Strong nuclear staining (+++) of CIAPIN1 in poorly
differentiated EOC tissues. (Original magnification, 200×).
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showed that CIAPIN1 expression was clearly elevated in
the eight EOC tissues compared with the paired non-
cancerous ovarian epithelial tissues (Figure 2A). The result
showed that expression of CIAPIN1 protein was signifi-
cantly higher than that in paired non-cancerous ovarian
epithelial specimens (Figure 2B, P< 0.01).
Correlation between the subcellular localization of
CIAPIN1 and clinicopathological features
The correlation between the subcellular localization of CIA-
PIN1 and clinicopathological features in EOC was further
evaluated. The nuclear expression level of CIAPIN1
increased from well-differentiated to poorly differentiatedFigure 2 CIAPIN1 expression in EOC and paired non-cancerous epithe
T, tumor tissue; N, paired non-cancerous epithelial tissue. β-actin was used
EOCs. CIAPIN1 had high expression in EOC, but low or no expression in pa
significance P< 0.01).EOC tissues (Figure 1b-d). In contrast, the level of CIA-
PIN1 cytoplasmic expression did not obviously differ be-
tween non-cancerous epithelial tissues and well or
moderately differentiated tumor tissues (Figure 1a-c). As
shown in Table 1, positive nuclear expression of CIAPIN1
positively correlated with the degree of differentiation, indi-
cating that the CIAPIN1 nuclear expression in poorly dif-
ferentiated cancer was significantly higher than that in well-
differentiated cancer (P< 0.0001). Moreover, the nuclear
expression was also significantly higher in patients with an
advanced FIGO stage (III + IV) than in those with an early
FIGO stage (I + II) (P=0.034). No significant association
was observed between CIAPIN1 nuclear expression and
patients’ age, lymph node metastasis or pathology subtypelial tissues by western blotting. (A) Eight representatives are shown.
as an internal control. (B) Analysis of the CIAPIN1 protein expression in
ired non-cancerous ovarian epithelial tissues (Paired EOC). (Statistical
Cai et al. World Journal of Surgical Oncology 2012, 10:112 Page 5 of 8
http://www.wjso.com/content/10/1/112(P> 0.05). In addition, no statistically significant correlation
between CIAPIN1 cytoplasmic expression and clinico-
pathological features was observed (see Additional file 1:
Table S1, P> 0.05).
Relationship between CIAPIN1 subcellular expression and
differentiation in EOC cell lines
The immunohistochemical results revealed that the nu-
clear expression of CIAPIN1 significantly increased from
well-differentiated to poorly differentiated EOC. Because
the A2780 cell line might be more poorly differentiated
than the HO8910 cell line [13], the subcellular distribution
of CIAPIN1 was also assessed in these cells. Immunofluor-
escence and immunohistochemical analyses (Figure 3)
demonstrated that the nuclear immunoreactivity of CIA-
PIN1 was strong in A2780 cells and weak in HO8910 cells.
However, no obvious difference in cytoplasmic immunor-
eactivity was observed in these cells.
Survival analysis
In univariate analysis (Table 2), CIAPIN1-positive nuclear
expression, histological differentiation and FIGO stage
were significantly associated with patient survival. Multi-
variate Cox proportional hazards regression analysis
(Table 3) indicated that nuclear expression of CIAPIN1
was an independent predictive factor for poor overall sur-
vival in EOC patients (HR=2.207, P< 0.0001). CIAPIN1
nuclear expression was then used to predict the post-
operative survival rate for EOC patients by Kaplan-Meier
analysis (Figure 4). Log rank analysis showed that the sig-
nificance in weak (+), moderate (++) and poor (+++) CIA-
PIN1 nuclear localization staining was 0.074, 0.008 and
<0.0001 compared with the negative staining group, re-
spectively; however, no statistically significant difference
was observed in the cytoplasmic expression of CIAPIN1
(see Additional file 1: Figure S1, P> 0.05). The 5-year sur-
vival rate of patients with negative (−) nuclear expressionFigure 3 Subcellular localization of CIAPIN1 in EOC cells. Morphology
(IHC) and immunofluorescence (IF). High nuclear intensity of CIAPIN1 ex
HO8910 cell lines.of CIAPIN1 was 90%, while the survival rate of patients
with weakly positive (+), moderately positive (++) and
strongly positive (+++) expression of CIAPIN1 was 50%,
33% and 16%, respectively.
Discussion
CIAPIN1 has been reported to be involved in proliferation
[8], multidrug resistance [14], angiopoiesis [6] and anti-
apoptosis [4,15] in many solid tumors and hematological
malignancies. The intracellular distribution of CIAPIN1
has been demonstrated to play a cell death-defying role in
a variety of mouse and human embryonic cells [4,5,7,9].
However, the subcellular distribution of CIAPIN1 in
tumors and the relationship between CIAPIN1 expression
and EOC had not been examined. The present study indi-
cated that CIAPIN1 nuclear localization is associated with
the histological differentiation, FIGO stage and prognosis
for EOC.
This study demonstrated that CIAPIN1 is highly
expressed in EOC tissues compared with paired non-
cancerous epithelial tissues by immunohistochemistry and
Western blotting. Consistently, CIAPIN1 has also been
found to be elevated in hepatocellular carcinoma [8] and
diffuse large B cell lymphoma [15]. These data indicate
that CIAPIN1 may play an oncogenic role in diverse can-
cers. More importantly, this study revealed that high nu-
clear expression of CIAPIN1 is significantly associated
with poor histological differentiation and an advanced
FIGO stage in EOC. However, no correlation between
CIAPIN1 cytoplasmic localization and clinical pathological
features was observed in the EOC tissues. Interestingly,
these results were in accordance with the observation that
the levels of CIAPIN1 nuclear expression in A2780 cells
were higher than those in HO8910 cells. The differenti-
ation status of the A2780 cell line has previously been
shown to be poorer than that of HO8910 [13]. Moreover,
one expression pattern might be strictly regulated by theanalysis of CIAPIN1 in EOC cell lines by immunohistochemistry
pression in A2780 cell lines and low nuclear intensity of CIAPIN1 in
Figure 4 Kaplan-Meier curves of postoperative survival of
patients with nuclear localization of CIAPIN1 expression.
Patients with high nuclear expression of CIAPIN1 in EOC; the survival
tended to a worse outcome compared to weak expression (log-rank
test P< 0.05).
Table 2 Univariate analysis of the association between
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alterations in function proteins, such as the subcellular
localization of LIMK1, cathepsin L and ALCAM altered
the prognosis of correlated cancers [16-18]. Thus, the
study findings suggested that the nuclear expression of
CAIPIN1 might be associated with the development of
poorly differentiated EOC. Proper transport of a protein
to its final destination is known to be crucial for the func-
tion of the protein [19]. The data from this study suggest
that CIAPIN1 nuclear localization is also associated with
carcinogenesis and differentiation in EOC, and at least
partially with poor clinical outcome of EOC patients.
These associations may be a result of the distinct differen-
tiation status of the EOC cells or interactions with specific
molecules. Further studies would be necessary to address






FIGO stage 1.598 0.959–2.665 0.072
Histological differentiation 0.978 0.708–1.350 0.892
Nucleus localization 2.003 1.443–2.781 <0.001distribution of CIAPIN1, but not the cytoplasmic distribu-
tion, plays an important role in EOC progression. We
hypothesize that nuclear CIAPIN1 expression may be
involved in neoplastic alterations, while the function of
the cytoplasmic protein does not contribute to cancer
progression.
This study demonstrated that CIAPIN1 expression has
prognostic value in several human tumors [8,9,15] and
revealed that patients with high levels of CAIPIN1 nuclear
expression displayed shorter postoperative survival times
than those with weak nuclear expression. This finding is in
accord with previous studies that have indicated that sub-
cellular localization is associated with poor prognosis in
other tumors [17,18]. The studies suggest that nuclear ex-
pression of CIAPIN1 is closely related to the poor prognosis
of patients with EOC. Moreover, multivariate Cox propor-
tional hazards regression analysis revealed that CIAPIN1
nuclear localization is an independent poor prognostic fac-
tor in EOC. These data demonstrate that CIAPIN1 nuclear
localization is a promising prognostic marker associated
with shorter overall survival in EOC. This information
might be useful for clinicians in providing individualized
therapy for EOC patients with optimal benefit. However,
the FIGO stage, pathological subtype and lymph node sta-
tus were poor prognostic factors according to Cox multi-
variate analysis. These variables may be potential predictive
factors for poor overall survival in EOC patients because of
the potential correlations between clinicopathological vari-
ables and CIAPIN1 nuclear localization. Moreover, the dif-
ferences may be caused by the cellular components among
the ovarian specimens. Further studies of additional patient
samples are necessary to address the significance of such
correlations.
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cated that CIAPIN1 is primarily localized in the nucleus
and, to a lesser extent, in the cytoplasm [20]. The nuclear
localization of CIAPIN1 is established either through spe-
cific nuclear localization signal sequences or via inter-
action with specific molecules. In fact, during mitosis,
CIAPIN1 cooperates with posttranslational modifications
of cell-cycle-dependent proteins, including cyclinD1
[21,22]. CyclinD1 can accelerate ovarian cancer carcino-
genesis [23-26]. Thus, we hypothesize that CIAPIN1 in
the nucleus might induce the development of EOC. In
addition, the interaction of CIAPIN1 with PICOT (PKCθ
interacting cousin of thioredoxin) at the N-terminal
regions might lead to the growth of Ba/F3 cells [27].
Moreover, phosphorylated PKC can activate proliferation
[28] and differentiation [29] through various signaling
pathways. Recent studies have demonstrated that the sta-
bility and anti-apoptotic function of CIAPIN1 are the re-
sult of interactions with TXNL2 and PICOT [20]. TXNL2
is involved in the activation of the c-Jun N-terminal kin-
ase/AP-1 and NF-kB pathways. These data imply that
molecules in the cytoplasm that interact with CIAPIN1
might play crucial roles in causing the translocation of
CIAPIN1 into the nucleus.
Conclusions
To our knowledge, this study is the first to associate the
subcellular expression of CIAPIN1 in EOC tissues with
clinical parameters and patient outcomes using immuno-
histochemical methods. The results suggest that CIAPIN1
nuclear accumulation might be responsible for EOC pro-
gression and is likely associated with the neoplastic out-
comes of EOC. The nuclear localization of CIAPIN1 may
represent a useful diagnostic and prognostic marker for
EOC.
Additional file
Additional file 1 Table S1. Correlation between CIAPIN1 cytoplasm
expression and clinical pathological parameters (P< 0.05 statistically
significant). Figure S1. Kaplan-Meier curves of postoperative survival of
patients with cytoplasmic localization of CIAPIN1 expression. Patients
with high cytoplasmic expression of CIAPIN1 in EOC; the survival was not
statistically significant (log-rank test, P> 0.05).
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